Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Phase 1
Terminated
- Conditions
- Graft Versus Host DiseaseLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesSecondary Myelofibrosis
- Interventions
- Procedure: Treg cell infusionProcedure: umbilical cord blood transplantationRadiation: total-body irradiation
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 3
- Registration Number
- NCT00376519
- Locations
- đşđ¸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Cancer
- Interventions
- Radiation: Total body irradiationOther: Natural killer cell infusionBiological: Interleukin-2
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 6
- Registration Number
- NCT00376805
- Locations
- đşđ¸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer
Phase 2
Withdrawn
- Conditions
- Breast Cancer
- Interventions
- Procedure: LumpectomyProcedure: dynamic contrast-enhanced magnetic resonance imagingProcedure: radiofrequency ablationRadiation: gadopentetate dimeglumine
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00373152
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
Phase 1
Terminated
- Conditions
- LeukemiaLymphomaGerm Cell TumorMultiple Myeloma and Plasma Cell Neoplasm
- Interventions
- Biological: keyhole limpet hemocyaninBiological: tetanus toxoid
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 19
- Registration Number
- NCT00369291
- Locations
- đşđ¸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy
Phase 2
Completed
- Conditions
- Lung Cancer
- Interventions
- Biological: bevacizumab
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 46
- Registration Number
- NCT00365547
- Locations
- đşđ¸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
đşđ¸Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States
Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
Phase 1
Completed
- Conditions
- Breast CancerLymphomaLeukemiaMyelodysplastic SyndromesKidney CancerMultiple Myeloma and Plasma Cell Neoplasm
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 148
- Registration Number
- NCT00365287
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Phase 2
Active, not recruiting
- Conditions
- Recurrent Childhood Acute Myeloid LeukemiaRefractory Anemia With Excess Blasts in TransformationRefractory AnemiaDe Novo Myelodysplastic SyndromeSecondary Myelodysplastic SyndromeChildhood Myelodysplastic SyndromeLeukemiaMyelodysplastic SyndromesSecondary Acute Myeloid LeukemiaRefractory Anemia With Excess Blasts
- Interventions
- Biological: filgrastimProcedure: umbilical cord blood transplantation
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 33
- Registration Number
- NCT00357565
- Locations
- đşđ¸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC
Phase 1
Terminated
- Conditions
- Lung Cancer
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 4
- Registration Number
- NCT00356941
- Locations
- đşđ¸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
Phase 2
Terminated
- Conditions
- LeukemiaMyelodysplastic Syndromes
- Interventions
- Biological: aldesleukinBiological: filgrastimBiological: natural killer cell (NK) therapyProcedure: Umbilical Cord Blood Transplantation (UCBT)Radiation: Total body irradiation (TBI)
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 16
- Registration Number
- NCT00354172
- Locations
- đşđ¸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
TBI Dose De-escalation for Fanconi Anemia
Phase 2
Completed
- Conditions
- Fanconi Anemia
- Interventions
- Procedure: Total Body IrradiationProcedure: Bone Marrow Transplantation
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 83
- Registration Number
- NCT00352976
- Locations
- đşđ¸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Š Copyright 2025. All Rights Reserved by MedPath